Search results
Man who took 40,000 ecstasy pills experienced years of terrible symptoms
UNILAD· 2 days agoThe man, known only as Mr. A, took roughly 40,000 tablets of ecstasy between the ages of 21 and 30....
Ecstasy’s path to approval for PTSD treatment faces doubts from FDA staff
Washington Post via Yahoo News· 2 days agoThe U.S. Food and Drug Administration released an analysis Friday that raised extensive questions...
FDA staff questions safety of ecstasy for PTSD
Axios· 2 days agoA Food and Drug Administration staff report questions the safety of using the drug known as ecstasy to treat PTSD, citing the potential for abuse and...
F.D.A.’s Review of MDMA Cites Health Risks and Study Flaws
New York Times· 2 days agoThe agency’s staff analysis suggests that approval of the illegal drug known as Ecstasy for...
Illegal ecstasy takes step toward becoming legal drug for PTSD
Medical Xpress· 2 days agoThe first new PTSD drug in over 20 years is up for approval. It will require U.S. regulators to do something they've never done before: greenlight the mind-altering—and illegal—party drug known ...
Drinking lots of water may seem like a healthy habit—here's when and why it can prove toxic
Medical Xpress· 1 day agoModels and celebrities often advocate drinking lots of water to help maintain clear, smooth skin....
FDA’s review of MDMA for PTSD highlights study bias and safety concerns
Ars Technica· 2 days agoThe safety and efficacy data on the use of MDMA (aka ecstasy) for post-traumatic stress disorder...
Psychoactive drugs like ketamine and MDMA are having a moment. The FDA will soon weigh in.
CBS News· 5 days agoLori Tipton is among the growing number of people who say that MDMA, also known as ecstasy, saved...
Psychedelic drug MDMA faces questions as FDA considers approval for PTSD
WJTV Jackson· 2 days agoWASHINGTON (AP) — Federal health regulators are questioning the safety and evidence behind the first...
FDA staff outline shortcomings of Lykos data for MDMA therapy
BioPharma Dive via Yahoo Finance· 2 days agoAhead of an advisory panel meeting, agency staff identified several sticking points in the clinical...